Only one OTC Markets Issuer Uplisted From The OTC To a senior exchange in June 2019. Learn more about the sole OTC ‘graduate’ below.
Artelo Biosciences, Inc. (Nasdaq: ARTL)
On June 21, 2019, ARTL uplisted from the OTCQB to the Nasdaq Capital Market. Artelo Biosciences is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system.
In connection with the uplisting, ARTL closed an $8 million underwritten public offering of 1,300,813 units at a price to the public of $6.15 per unit. Maxim Group LLC acted as the Sole Book-Running Manager and Joseph Gunnar & Co. acted as co-manager for the offering.